Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…
(Reuters)—The U.S. Food and Drug Administration says it has approved Amgen’s osteoporosis treatment for postmenopausal women who are at high risk of fracture. Evenity (romosozumab-aqqg), developed jointly with Belgium-based UCB SA, helps reduce the risk of fracture by increasing bone mass and mildly inhibiting the break down of bone minerals. Romosozumab-aqqg belongs to a new…
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…
Health Canada has approved adalimumab for treating chronic non-infectious anterior uveitis in patients 2 years and older…
SM04690, an intra-articular injection for knee OA, will soon enter phase 3 trials to assess its effects on pain, joint function and disease…
The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…
CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center…
The FDA has issued a boxed warning for febuxostat after a safety study found an increased risk of heart-related and other death in RA patients…
According to the FDA, an ongoing safety trial found higher dose tofacitinib increased the risks of pulmonary embolism and death in RA patients…